<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083366</url>
  </required_header>
  <id_info>
    <org_study_id>96153</org_study_id>
    <nct_id>NCT03083366</nct_id>
  </id_info>
  <brief_title>Sacral Nerve Stimulation in Improving Bladder After Acute Traumatic Spinal Cord Injury</brief_title>
  <official_title>The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life After Acute Traumatic Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the first 3 months after spinal cord injury, patients will be randomized to receive and
      implantable sacral neuromodulator that will stimulate bilateral S3 nerve roots. These
      patients will be compared to those receiving standard neurogenic bladder care. Multiple
      primary and secondary endpoints will be compared based upon urodynamic parameters, quality of
      life measurements, and clinical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM 1: To determine the effect of sacral neuromodulation on urodynamic parameters following
      acute spinal cord injury. The following outcomes will be evaluated by urodynamic assessment
      at one year post-SCI: (1) maximum cystometric capacity, (2) bladder compliance, (3) presence
      of detrusor overactivity, and (4) volume and pressure for first detrusor contraction.

      AIM 2: To assess the impact of sacral neuromodulation on patient-reported quality of life
      after acute spinal cord injury. Patient-reported QoL will be assessed using the SCI-QOL
      bladder question bank and bladder/voiding diaries. Mean SCI-QOL score, daily number of
      catheterizations, average catheterization volume, and episodes of incontinence per day will
      be compared between groups at one year post-SCI.

      AIM 3: To examine the impact of sacral neuromodulation on quantifiable clinical outcomes.
      Patients will be followed longitudinally during the study period and assessed for the
      following: (1) need for anti-cholinergic medications and/or onabotulinum toxin A treatment,
      (2) number of symptomatic UTIs per year, (3) complications attributable to the device, (4)
      need for revision of device or leads due to lead migration or failure, (5) development of
      hydronephrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized non-blinded study of sacral neuromodulation plus standard neurogenic bladder care versus standard neurogenic bladder care in patients with spinal cord injury</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urodynamic determined maximum cystometric capacity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life differences measured by mean SCI-QoL</measure>
    <time_frame>3, 6, 9, 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of urinary tract infections per year</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urodynamics determined maximum cystometric capacity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urodynamics determined bladder compliance</measure>
    <time_frame>3, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of detrusor overactivity during urodynamics</measure>
    <time_frame>3, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urodynamics determined volume at first detrusor contraction</measure>
    <time_frame>3, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urodynamics determined detrusor pressure at first detrusor contraction</measure>
    <time_frame>3, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of daily catheterizations</measure>
    <time_frame>3, 6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average catheterization volume</measure>
    <time_frame>3, 6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence episodes per day</measure>
    <time_frame>3, 6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour pad weight test</measure>
    <time_frame>3, 6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hydronephrosis</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for anticholinergic medication</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for onabotulinum toxin A injection</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for device revision</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for device explanation</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urologic related surgeries</measure>
    <time_frame>continous, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>continuous, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spinal Cord Injury, Acute</condition>
  <condition>Neurogenic Bladder</condition>
  <condition>Incontinence</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Sacral neuromodulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard neurogenic bladder care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)</intervention_name>
    <description>Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)</description>
    <arm_group_label>Sacral neuromodulation</arm_group_label>
    <other_name>Sacral neuromodulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Ability to implant device less than 12 weeks post-SCI

          -  Presence of acute SCI at or above T12

          -  ASIA Scale A or B

          -  Expectation to perform CIC personally or have caretaker perform CIC

        Exclusion Criteria:

          -  Inability to perform CIC

          -  Pre-existing SCI

          -  Pre-existing progressive neurological disorder

          -  Autonomic dysreflexia

          -  Prior sacral back surgery

          -  Posterior pelvic fracture with distortion of the sacroiliac joint

          -  Prior urethral sphincter or bladder dysfunction

          -  Chronic urinary tract infections prior to SCI

          -  Pregnancy at the time of enrollment

          -  Presence of coagulation disorder or need for anticoagulation that they cannot be
             stopped temporarily for procedure

          -  Any significant co-morbidity or illness that would preclude their participation or
             increase the risk to them having a surgical procedure

          -  Active untreated infection

          -  Traumatic injury to the genitourinary system

          -  Prior pelvic radiation, bladder cancer or other surgical procedure to the bladder that
             would effect baseline bladder physiology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashlea Wilkes, BA</last_name>
    <phone>801-213-2700</phone>
    <email>Ashlea.Wilkes@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Lignell, BA</last_name>
    <phone>801-213-2700</phone>
    <email>Elizabeth.Lignell@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Covalschi, MS</last_name>
      <phone>734-763-7144</phone>
      <email>dcovalsc@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>John Stoffel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Ayd, BS</last_name>
      <phone>612-703-3111</phone>
      <email>plan0067@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Sean P Elliott, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashlea Wilkes, BA</last_name>
      <phone>801-213-2700</phone>
      <email>Ashlea.Wilkes@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Lignell, BA</last_name>
      <phone>801-213-2700</phone>
      <email>Elizabeth.Lignell@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy B Myers, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Lenherr, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Jeremy Myers</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>Neurogenic</keyword>
  <keyword>bladder</keyword>
  <keyword>electrical stimulation</keyword>
  <keyword>neuromodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

